MERGENT® OTC INDUSTRIAL

NEWS REPORTS

Tuesday, January 21, 2025

Volume 56 No. 1



NOTICE – Items in this issue will be listed online weekly and printed monthly.

			NOI	ICE – Items in inis issue i	viii be iistea o	пипе wеекіу а	па ргіпіва т	ontniy.			
ADOBE INC				income taxes -				translation			
Annual Report				domestic			1,958,000	adjustments	(33,000)	22,000	(105,000)
Consolidated Incom				Income before				Basic EPS Excluding			
	11/29/24	12/01/23	12/02/22	income taxes -			4.050.000	ExtraOrdinary Items	\$12.43	\$11.87	
Sales and Marketing	5,764,000			foreign	• • • •	• • • •	4,050,000	Diluted EPS Excluding ExtraOrd			
General and	3,704,000	•••	•••	before income taxes	6,931,000	6,799,000	6,008,000	Items	\$12.36	\$11.82	
administrative	1,529,000			Current provision	-,,	-,,	-,,		4	4	
Revenue -				for (benefit of)				As is; As of January	6, 2023		
subscription		18,284,000	16,388,000	income taxes- U.S.	1 202 000	1 100 000	465,000	Consolidated Balance S		rs Ended (\$00	00):
Revenue - product Services & support		460,000 665,000	532,000	federal	1,292,000	1,198,000	465,000		,	11/29/24	12/01/23
Revenue - services	•••	005,000	•••	for (benefit of)							
& other			686,000	income				Cash		787,000	618,000
Trade sales	386,000			taxes-foreign	315,000	335,000	329,000	Cash & cash equivalents Cash & cash equivalents		7,613,000	7,141,000
Total revenue	21,505,000	19,409,000	17,606,000	Current provision for (benefit of)				Marketable equity		7,013,000	•••
subscription		1,822,000	1,646,000	income taxes-state				securities			701,000
Cost of revenue -	•••	1,022,000	1,010,000	& local	232,000	260,000	132,000	Short-term investments		273,000	
product	25,000	29,000	35,000	Total current				Trade receivables, gross		2,086,000	2,240,000
Cost of				provision for				Allowances for doubtful accounts		14,000	
revenue-services &		503,000		(benefit of) income	1,839,000	1,793,000	926,000	Trade receivables net		2,072,000	
support	• • • •	303,000		Deferred provision	1,839,000	1,793,000	920,000	Doubtful Account			16,000
services & other			484,000	for (benefit of)				Total receivables, net			2,224,000
Total cost of				income taxes-U.S.				Prepaid expenses & other			1.019.000
revenue	2,358,000	2,354,000	2,165,000	federal	(580,000)	(556,000)	(45,000)	current assets			1,018,000
Gross profit (loss) Research &	19,147,000	17,055,000	15,441,000	Deferred provision for (benefit of)				other current assets		1,274,000	
development				income				Total current assets		11,232,000	11,084,000
expenses	3,944,000	3,473,000	2,987,000	taxes-foreign	179,000	227,000	360,000	Computers & other			.=
Sales & marketing				Deferred provision				equipment		146,000	171,000
expenses		5,351,000	4,968,000	for (benefit of)				Capital projects in-progress		27,000	2,000
General & administrative				income taxes-state & local	(67,000)	(93,000)	11.000	Leasehold improvements .		222,000	275,000
expenses		1,413,000	1,219,000	Total deferred	(67,000)	(93,000)	11,000	Land		163,000	163,000
Amortization of		-,,	-,,	provision for				Buildings		1,067,000	1,069,000
intangibles	169,000	168,000	169,000	(benefit of) income				Building improvements Computer Software		561,000	591,000 1,490,000
Acquisition	1 000 000			taxes	(468,000)	(422,000)	326,000	Total property &		1,405,000	1,490,000
termination fee Total operating	1,000,000	• • • •	• • • •	Net Income After Taxes	5,560,000			equipment, gross		3,591,000	3,761,000
expenses			9,343,000	Provision for	3,300,000	•••	•••	accumulated depreciation			
Operating income			.,,	(benefit from)				and amortization		1,655,000	
(loss)	6,741,000	6,650,000	6,098,000	income taxes	1,371,000	1,371,000	1,252,000	Less: accumulated depreciation &			
Interest income	341,000	269,000		Net income (loss)	5,560,000	5,428,000	4,756,000	amortization			1,731,000
Foreign exchange gains (losses)	(29,000)			Weighted average shares outstanding				Property and equipment,			
Foreign exchange	(25,000)	• • • • • • • • • • • • • • • • • • • •	•••	- basic	447,000	457,000	469,500	net		1,936,000	• • •
gains (losses)		(17,000)		Weighted average				Property & equipment,			2.030,000
Realized gains on				shares outstanding	450.000	450,000	450.000	net Operating lease			2,030,000
fixed income investment	12,000			- diluted Year end shares	450,000	459,000	470,900	right-of-use assets, net		281,000	358,000
Realized losses on	12,000	•••	•••	outstanding	441,000	455,000	462,000	Goodwill		12,788,000	12,805,000
fixed income				Net income (loss)	,	,	,	Other Intangibles, net		782,000	
investment	(1,000)			per share - basic	\$12.43	\$11.87	\$10.13	Other intangibles, net		1 554 000	1,088,000
Interest expense	169,000	113,000	112,000		¢12.26	611.02	¢10.10	Other assets		1,554,000 1,657,000	1,223,000 1,191,000
Investment gains (losses), net		16,000	(19,000)	per share - diluted Full-Time Employees	\$12.36	\$11.82	\$10.10	Total assets		30,230,000	29,779,000
Other income	•••	10,000	(13,000)	(Period End)	30,709			Trade payables			314,000
(expense), net		246,000	41,000	Total number of	-0,.07	•••		Accrued compensation &		645.005	505.000
Gain (loss) on				employees	30,709	29,945	$\square_{29,239}$	benefits		646,000 575,000	535,000
real-estate	26.000	(7.000)		Number of common				Accrued bonuses		5/5,000 141,000	547,000 111,000
partnership Other	36,000 311,000	(7,000) 1,000		stockholders	856	905	112 ₉₂₈	Accrued corporate		111,000	111,000
Investment gains	211,000	1,000	•••	Subscription Service and Other	20,521,000 598,000	• • • •	• • • •	marketing		176,000	132,000
(losses), net	48,000			Subscription	1,799,000			Taxes payable		500.000	122,000
Total non-operating				Services and	1,,000	•••	•••	Other accrued expenses Accounts payable &		509,000	495,000
income (expense),	100.000	140.000	(00,000)	support	534,000			accrued expenses		361,000	
net Income before	190,000	149,000	(90,000)	Foreign currency				Income taxes payable		119,000	85,000
media beroic											

2023

2023

Operating lease	75 000	72 000
liabilities	75,000 6,131,000	73,000 5,837,000
Sales and use taxes	121,000	
Debt	1,499,000	
Derivative collateral liabilities	168,000	
Total current liabilities	10,521,000	8,251,000
Notes	4,129,000	3,634,000
Deferred revenue	128,000	113,000
Income taxes payable	548,000	514,000
Operating lease	252.000	272.000
liabilities	353,000 446,000	373,000 376,000
Total liabilities	16,125,000	13,261,000
Common stock	60	60
Additional	•••	00
paid-in-capital	13,419,000	11,586,000
Common stock & additional paid-in		
capital	(60)	
Retained earnings	38,470,000	
Retained earnings (accumulated deficit)		33,346,000
Unrealized gains on	•••	33,340,000
available-for-sale		
securities Net unrealized gains	(1,000)	(12,000)
(loss) on derivative		
instruments designated as	00.000	(26,000)
hedging instruments Cumulative foreign	80,000	(26,000)
currency translation		
adjustments	(280,000)	(247,000)
Accumulated other comprehensive income		
(loss)	(201,000)	
Accumulated other comprehensive income		
(loss)		(285,000)
Treasury stock	37,583,000	
Treasury stock, at cost Total stockholders'		28,129,000
equity (deficit)	14,105,000	16,518,000
Stockholders equity	14,105,000	16,518,000
Recent Dividends: 1. Adobe Inc common. No dividends paid. Annual Dividends: 1. Adobe Inc common. No dividends paid. ANGIODYNAMICS INC		
Earnings, 6 mos. to Nov 30(Consol.	- \$000): 2024	2023
Total Revenues	140,336	157,752
Net Sales		157,752
Cost & expenses	159,396 (24,192)	128,655 22,243
Interest expense		(653)
Other income (expense), net	(161)	(320)
Net before taxes	(23,513)	22,243 5,407
Net income	(23,536)	16,836
Earnings common share Primary	. \$(0.58)	\$0.42
Fully Diluted		\$0.42
Common Shares:	40.707	40.102
Full DilutedYear-end		40,103 40,224
	,	,
CHS INC Farrings 3 mas to Nav 30/Consol	\$0002÷	
Earnings, 3 mos. to Nov 30(Consol.	- \$000): 2024	2023
Total Revenues	9,294,112	11,390,658
Net Sales	9,156,286	11,390,658 10,997,764
Operating income	137,826	392,894
Interest expense		29,628
Other income (expense), net	148,659 258,837	153,580 516,846
		210,040

Income taxes	13,244	(6,522)
Net income	245,593	523,368
Earnings common share		
Common Shares:		
Consolidated Balance Sheet Items, as	of (\$000):	
Assets:		2024
Cash & equivalents		450,491
Inventories		3,901,294
Current assets		9,358,224
Net property & equip		5,239,387
Total assets		19,576,088
Liabilities:		
Current liabilities		6,069,387
Long-term debt		1,821,746
Stockholders' equity		10,812,419
Net current assets		3,288,837
CINTAS CORPORATION		

Earnings, 6 mos. to Nov 30(Consol. - \$000): 2024

	2021	202.
Total Revenues	5,063,370	4,719,507
Cost & expenses	3,910,949	3,719,268
Operating income	1,152,421	1,000,239
Interest income		1,191
Interest expense		51,134
Net before taxes	1,102,349	950,296
Income taxes	201,821	190,598
Net income	900,528	759,698
Balance for common	897,346	756,741
Earnings common share		
Primary	\$2.22	\$7.43
Fully Diluted	\$2.19	\$7.32
Common Shares:		
Full Diluted	410,613	103,418
Year-end	403,496	101,348

COMTECH TELECOMMUNICATIONS CORP.

Earnings, 3 mos. to Oct 31(Consol. - \$):

	2024	2023
Total Revenues	15,800,000	151,911,000
Net Sales		151,911,000
Cost & expenses	38,377,000	144,536,000
Operating income	29,170,000)	2,086,000
Interest expense		4,932,000
Other income (expense), net		65,000
Gains or losses	(5,524,000)	
Net before taxes	16,273,000)	(2,781,000)
Income taxes	2,134,000	(1,344,000)
Net income	18,407,000)	(1,437,000)
Balance for common(15	55,862,000)	
Earnings common share		
Primary	\$(5.29)	\$(0.11)
Fully Diluted	\$(5.29)	\$(0.11)
Common Shares:		
Full Diluted	29,446,000	28,745,000
Year-end	28,893,810	28,235,465
Consolidated Balance Sheet Items, as	of (\$):	
Assets.		2024

Consolidated Balance Sneet Items, as of (5):	
Assets:	2024
Cash & equivalents	29,644,000
Inventories	81,804,000
Current assets	306,556,000
Net property & equip	46,433,000
Total assets	793,203,000
Liabilities:	
Current liabilities	383,313,000
Stockholders' equity	299,064,000
Net current assets	(76,757,000)

EXELON CORP

Dividend Announcement On Oct. 29, 2024, Co.'s Board of Directors declared a regular quarterly dividend of \$0.38 per share on Co.'s common stock, payable on Dec. 13, 2024, to Co.'s shareholders of record as of the close of business on Nov. 11, 2024.

EXELON CORP

Notes Sold On Feb. 27, 2024, Co. issued and sold \$1.7 billion in aggregate principal amount of Notes. The Notes were issued under an indenture, dated as of June 11, 2015 between Co. and The Bank of New York Mellon Trust Company, N.A., as trustee, as amended and supplemented by the Seventh Supplemental Indenture, dated as of Feb. 27, 2024 A portion of the net proceeds from the sale of the Notes, together with available cash balances, will be used to repay \$500 million of ExelonSs outstanding term loan maturing in April 2024 and bearing interest at the Secured Overnight Financing Rate (SOFR) plus 0.85% and \$689 million

of Exelon's currently outstanding commercial paper borrowings having an approximate weighted average interest rate of 5.600% per annum as of Feb. 16, 2024. The remainder of the net proceeds will be used for general corporate purposes. The 2029 Notes will pay interest at the fixed rate of 5.150% per annum, the 2034 Notes will pay interest at the fixed rate of 5.450% per annum and the 2053 Notes will pay interest at the fixed rate of 5.600% per annum. Interest on the Notes will be payable semi-annually on Mar. 15 and Sept. 15 of each year, beginning on Sept. 15, 2024, in the case of the 2029 Notes and 2034 Notes, and Mar.15, 2024, in the case of the 2053 Notes. The 2029 Notes will mature on Mar. 15, 2029, the 2034 Notes will mature on Mar. 15, 2034 and the 2053 $\,$ Notes will mature on Mar. 15, 2053.

EXELON CORP

Official Changes On Feb. 29, 2024, Co. announced the retirement of Doug Brown, senior vice president and chief investment officer effective July 1, 2024.

EXELON CORP

Official Changes On Oct. 17, 2024, Co. announced the promotion of Cynthia McCabe to senior vice president, chief of staff and chief communications officer, effective Nov.1, 2024.

EXELON CORP

Official Changes On Dec. 3, 2024, Co. announced that Gayle Littleton will cease serving as Co.'s Executive Vice President, Chief Legal Officer and Corporate Secretary effective Jan. 1, 2025. Effective Jan. 1, 2025, Colette Honorable, currently Co.'s Executive Vice President, Public Policy and Chief External Affairs Officer, will be named Chief Legal Officer and Corporate

HURCÓ COMPANIES INC

Annual Report Consolidated Income (\$000):	Statement,	Years Ended	Oct. 31
(φοσο):	2024	2023	2022
Sales & service		227 907	250 914
fees		227,807	250,814
fees	186,584		
Total revenues	186,584	227,807	
Cost of sales &	,	,	
service			186,336
Cost of sales -			
restructuring		171,639	
Gross profit	37,743	56,168	64,478
Selling, general			
and administrative	46.020		
expenses	46,029	• • • •	
administrative			
expenses			51,731
Restructuring			,
expense (credit) &			
other expense, net		49,552	
Operating income			
(loss)	(8,286)	6,616	12,747
Interest expense	578		
Interest expense		282	27
Interest Income	621	369	 79
Investment income		61	174
Income from equity		01	1/4
investments	292		
Income (loss) from			
equity investments		494	733
Other income			
(expense), net	(1,979)	(504)	(1,828)
Income (loss)			
before income taxes - domestic			(232)
Income (loss)	• • • •		(232)
before income taxes			
- foreign			12,110
Income (loss)			, -
before income taxes	(9,850)	6,754	11,878
Current state			
income tax			
provision (benefit)	647	(431)	
Current U.S. income			
tax provision			1,092
(benefit)	• • • •	• • • •	1,092
income tax			
provision (benefit)	1,804	2,775	3,191
	*	,	

Total current				Inventories, net		157,952	Recent Dividends:
income tax	2.451	2 244	4.202	Derivative assets	323	740	1. Hurco Companies Inc common (stated value: \$0.10).
provision (benefit) Deferred state	2,451	2,344	4,283	Prepaid & other assets	5,209	7,789	ExDate Amt Declared Record Payable
income tax				Total current assets	228,577	248,230	12/31/2021 0.14 11/12/2021 01/03/2022 01/17/2022
provision (benefit)	(3,765)	104		Land	1,046	1,046	03/25/2022 0.15 03/11/2022 03/28/2022 04/11/2022
Deferred U.S.				Building	7,381	7,387	06/24/2022 0.15 06/10/2022 06/27/2022 07/11/2022
income tax provision (benefit)			(933)	Machinery & equipment	28,106 4,667	26,779 4,473	09/30/2022 0.15 09/15/2022 10/03/2022 10/17/2022 12/30/2022 0.15 11/15/2022 01/03/2023 01/17/2023
Deferred foreign	•••	•••	(755)	Property & equipment,	1,007	.,.,,	03/24/2023 0.16 03/10/2023 03/27/2023 04/10/2023
income tax				gross	41,200	39,685	06/23/2023 0.16 06/09/2023 06/26/2023 07/10/2023
provision (benefit) Total deferred	(518)	(83)	302	Accumulated depreciation and amortization	32,404		09/29/2023 0.16 09/15/2023 10/02/2023 10/16/2023 12/29/2023 0.16 11/10/2023 01/02/2024 01/16/2024
income tax				Less: accumulated	32,404	• • • •	03/27/2024 0.16 03/15/2024 03/29/2024 04/12/2024
provision (benefit)	(4,283)	21	(631)				
Net (loss) income	(16,608)			amortization		30,826	Annual Dividends:
Income Taxes - Other -				Total property and equipment	8,796		1. Hurco Companies Inc common (stated value: \$0.10).
Deferred/Current	8,590			Total property &	0,770	•••	20220.59 20230.63 20240.32
Provision (benefit)				equipment, net		8,859	
for income taxes	6,758	2,365	3,652	Software development		7.020	INGLES MARKETS INC
Net income (loss) Undistributed	(16,608)	4,389	8,226	costs, gross	•••	7,030	Annual Report
earnings allocated				costs	7,044		Consolidated Income Statement, Years Ended (\$): 09/28/24 09/30/23 09/24/22
to participating				Intangible assets, net	763		09/20/24 09/30/25 09/24/22
shares	• • • •	61	97	Intangible assets, net	• • • •	994	Net sales
Net income (loss) applicable to				Operating lease - right-of-use assets, net	11,313	10,971	Net sales
common shareholders			8,129	Deferred income taxes	1,349	4,749	Cost of goods sold 4,339,774,157
Weighted average				Investments & other			Gross profit (loss) 1,299,835,277 1,404,915,214 1,415,768,360
shares outstanding - basic	6,489	6,499	6,580	assets, net	5,300	9,756 5,100	Operating &
Weighted average	0,409	0,499	0,560	Equity method investment Investments and other	3,300	3,100	administrative
shares outstanding				assets	10,801		expenses
- diluted	6,489	6,528	6,632	Investments and other			sale or disposal of
Year end shares outstanding	6,436	6,462	6,567	assets, net - Balancing value	5,501		assets
Earnings (loss) per	0,430	0,402	0,507	Investments and other	3,301	• • • •	Income (loss) from
share - continuing				assets, net - Balancing			operations 147,144,231 292,304,132 376,932,584 Other income
operations - basic	\$(2.56)	\$0.67		value	269.642	4,656	(expense), net 14,216,870 8,269,117 5,845,479
Net earnings (loss) per share - basic	\$(2.56)	\$0.67	\$1.24	Total assets	268,643 24,951	290,589 28,544	Total interest
Net earnings (loss)	Φ(2.50)	ψ0.07	Ψ1.21	Accounts payable -	21,751	20,511	costs
per share - diluted	\$(2.56)	\$0.66	\$1.23	related parties		1,117	capitalized
Common DPS - by				Customer deposits	4,308	2,827	Interest expense 21,859,800 22,068,290 21,508,135
Period End Date - Gross	\$0.32			Derivative liabilities	705	1,821	Income (loss)
Dividends paid per	ψ0.52	•••	•••	liabilities	3,829	3,712	before income taxes 139,501,301 278,504,959 361,269,928 Current federal
share		\$0.63	\$0.59	1 5			income tax expense
Number of full time	600	716	¹¹² 735	employee benefits	7,786 866	9,853 1,713	(benefit)
employees Total number of	688	716	/33	Accrued expenses	4,258	4,092	Current state income tax expense
employees	688			Accrued warranty expenses	1,086	1,294	(benefit)
Number of common			ma.	Total current liabilities	47,789	54,973	Total current
stockholders	119	119	¹¹³ 110	Deferred income taxes	53 537	83 1,293	income tax expense
Foreign currency translation				Operating lease	557	1,2,5	(benefit)
adjustments	3,474	3,274	(19,591)	liabilities	7,852	7,606	income tax expense
Cost of sales and		•		Deferred credits and other	5,240		(benefit) (565,000) (5,802,000) (3,565,000)
service	148,841	•••	• • • •	Deferred credits and	3,240	• • • •	Deferred state
Diluted EPS Excluding ExtraOrd				other		4,403	income tax expense (benefit) (767,000) (856,000) (744,000)
Items	\$(2.56)	\$0.66		Total non-current	12.602	12 205	Total deferred
Investment (loss)	00			liabilities	13,682 644	13,385	income tax expense
income	80	•••	• • • • • • • • • • • • • • • • • • • •	Common stock		646	(benefit)
As is; Approximate	ly: 3 As of De	acambar 31 2	022	Additional paid-in			income taxes 105,541,301
Consolidated Balance	•			capital	61,500	61,665	Income tax expense
Consolidated Balance	Silect, Italis	2024	2023	Retained earnings	161,422		(benefit)
				(accumulated deficit)		180,124	Net income (loss) 105,541,301 210,811,959 272,758,928 Weighted average
Cash and cash equivalents		33,330	41 704	Foreign currency	(14.511)		class A shares
Cash & cash equivalents. Accounts receivable,			41,784	translation	(14,511) (1,883)	• • • •	outstanding - basic 14,330,809
gross		38,160	41,483	Accumulated other	(1,003)	•••	Weighted average class B shares
Less: allowance for		4 400		comprehensive loss	(16,394)		outstanding - basic 4,663,567
doubtful accounts		1,482	1,518	Accumulated other			Weighted average
Accounts receivable, net . Accounts receivable, net .		36,678	39,965	comprehensive income (loss)		(20,204)	shares outstanding
Raw materials		35,385		Total shareholders'		(20,204)	- basic
Purchased parts &			27.151	equity (deficit)	207,172	222,231	class A shares
sub-assemblies Work-in-process		13,428	37,161 16,217	Rep Total Equity &	207 172	222 221	outstanding -
Finished goods		104,224	104,574	Minority Interest	207,172	222,231	diluted
Inventories		153,037					Weighted average

class B shares				accumulated depreciation			liabilities		47,444,876
outstanding -			4.663.567	and amortization	1,755,678,940	• • •	Total liabilities		1,014,873,593
diluted	• • • •		4,003,307	Less accumulated depreciation &			Class A common stock	,	724,854
Weighted average shares outstanding				amortization		1,679,348,970	Accumulated other	222,472	224,865
- diluted	18,994,376	18,994,376		Property and Equipment -	• • • •	1,679,348,970	comprehensive income	6,737,631	
Year end shares	10,774,370	10,774,370	•••	Net	1,526,708,462		Accumulated other	0,737,031	•••
outstanding	18,994,376	18,994,376	18,994,376	Property & equipment,	1,520,700,402	•••	comprehensive income		
Earnings per share	10,771,570	10,771,570	10,221,370	net		1,431,872,289	(loss)		13,233,631
from continuing				Operating lease right of	•••	1,151,072,209	Retained Earnings		15,255,651
operations - basic	\$5.56	\$11.10		use assets	27,247,555	39,602,202	Retained earnings	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Net earnings (loss)				Other assets	48,378,943	49,814,897	(accumulated deficit)		1,444,788,790
per class A common				Total assets	2,527,882,715	2,473,845,733	Total stockholders'		
share - basic			\$14.69	Current portion of			equity (deficit)	. 1,545,749,090	1,458,972,140
Net earnings (loss)				long-term debt	17,520,876		Total Equity	1,545,749,090	
per class B common				Current portion of					
share - basic			\$13.35	long-term debt		17,526,289			
Net earnings per				Current portion of			Recent Dividends:		
share - basic	\$5.56	\$11.10		operating lease			1. Ingles Markets Inc class B co	mmon.	
Earnings per share				liabilities	4,995,837	7,594,971	No dividends paid. 2. Ingles Markets Inc class A co	mmon	
from continuing				Accounts payable - trade	198,329,197	204,040,546	2. Higies Markets file class A co	minion.	
operations -	05.56	611.10		Property, payroll, &		25 202 001	ExDate Amt Declared	Record	Payable
diluted	\$5.56	\$11.10		other taxes payable		25,203,091		01/06/2022	
Net earnings (loss)				Salaries, wages, &	40.060.002	50.026.142		2 04/07/2022	
per class A common			¢14.26	bonuses payable	48,869,003	50,836,143		2 07/07/2022	
Share - diluted	• • • •	•••	\$14.36					2 10/06/2022	
Net earnings (loss)				liabilities - employee		4 526 200		2 01/06/2023	
per class B common share - diluted			\$13.35	group insurance	• • • • • • • • • • • • • • • • • • • •	4,536,309		3 04/06/2023	
Net earnings per	• • • •		\$13.33	liabilities - workers'				3 07/06/2023	
share - diluted	\$5.56	\$11.10		compensation insurance		4,711,748		3 10/12/2023	
Cash dividends per	φ5.50	φ11.10	•••	Self-insurance	•••	7,/11,/40		1 01/12/2024	
class A common				liabilities - general				1 04/11/2024	
share			\$0.66	liability insurance		4,726,301	07/11/2024 0.17 07/01/2024	1 07/11/2024	07/18/2024
Cash dividends per	•••	•••	ψ0.00	Interest	99,101,275	5,111,666	10/10/2024 0.17 09/30/2024	10/10/2024	10/17/2024
class B common				Other accrued expenses &)),101,2 <i>1</i> 3	3,111,000	01/09/2025 0.17 12/30/2024	1 01/09/2025	01/16/2025
share			\$0.60	current portion of other					
Full-Time Employees	26,360			long-term liabilities		5,610,526	Annual Dividends:		
Total number of	-,			Accrued expenses &		- , ,	1. Ingles Markets Inc class B co	mmon.	
employees	26,360	26,420	¹¹ 26,000	current portion of other			No dividends paid.		
Number of common	20,500	20,.20	20,000	long-term liabilities		100,735,784	2. Ingles Markets Inc class A co	mmon.	
stockholders -				Other	6,177,911				
class A			$\square \square_{331}$	Current portion of			20220.66 2023	0.66 2024	0.66
class A			□□ ₃₃₁	Current portion of finance lease liabilities	674,759	635,559	20250.17	0.66 2024	0.66
Number of common	•••		□□331		674,759	635,559			0.66
Number of common stockholders -				finance lease liabilities	674,759 22,592,669	635,559	20250.17		0.66
Number of common stockholders - class B			©©331	finance lease liabilities	,	635,559	20250.17 LEXARIA BIOSCIENCE CORP	ol. – \$): 2024	
Number of common stockholders - class B Number of				finance lease liabilities	22,592,669		20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso	ol. – \$): 2024 183,923	2023 151,278
Number of common stockholders - class B Number of beneficiary				finance lease liabilities. Property, payroll and other taxes payable. Interest. Accrued expenses and current portion of other	22,592,669		20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024 183,923	2023 151,278 151,278
Number of common stockholders - class B Number of	392	405	□2 ₉₉	finance lease liabilities. Property, payroll and other taxes payable. Interest. Accrued expenses and current portion of other long-term liabilities -	22,592,669 4,984,248		20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024 183,923 	2023 151,278 151,278 1,290,420
Number of common stockholders - class B Number of beneficiary stockholders				finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value	22,592,669 4,984,248 16,477,444		20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024 183,923 2,890,551 (2,706,628)	2023 151,278 151,278 1,290,420 (1,185,038)
Number of common stockholders - class B Number of beneficiary stockholders Total revenues	392	405	□2 ₉₉	finance lease liabilities. Property, payroll and other taxes payable. Interest. Accrued expenses and current portion of other long-term liabilities - Balancing value. Total current liabilities.	22,592,669 4,984,248 16,477,444 320,621,944	330,533,149	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	bl. – \$): 2024 183,923 2,890,551 (2,706,628)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319
Number of common stockholders - class B	392	405	□2 ₉₉	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000	 330,533,149 67,187,000	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	bl. – \$): 2024 183,923 2,890,551 (2,706,628)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215)
Number of common stockholders - class B	392 5,639,609,434	405	□2 ₉₉	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000	330,533,149	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income	bl. – \$): 2024 183,923 2,890,551 (2,706,628)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215)
Number of common stockholders - class B	392 5,639,609,434	405 	□2 ₉₉	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000	330,533,149 67,187,000 350,000,000	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038)
Number of common stockholders - class B	392 5,639,609,434	405	□2 ₉₉	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000	 330,533,149 67,187,000	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	bl \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13)
Number of common stockholders - class B	392 5,639,609,434 \$0.66	405 	□2 ₉₉	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds. Notes payable due to	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	bl \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13)
Number of common stockholders - class B	392 5,639,609,434 \$0.66	405 	□2 ₉₉	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares:	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13)
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047	405 \$0.66	 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) \$(0.16)	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13)
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047	405 \$0.66	 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705)	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) 16,668,513 17,452,594	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13)
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembo	\$0.66	 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) 16,668,513 17,452,594	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembo	\$0.66 er 21, 2022 rs Ended (\$):	 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembo	\$0.66	 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses. Net income Earnings common share Primary. Fully Diluted Common Shares: Full Diluted. Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembers Sheet, Year	\$0.66 er 21, 2022 rs Ended (\$): 09/28/24	 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$\frac{1}{2}\$ \$\frac{1}{2}\$ \$\frac{202}{2}\$ \$\frac{1}{2}\$ \$\frac{1}{2	 	finance lease liabilities. Property, payroll and other taxes payable. Interest. Accrued expenses and current portion of other long-term liabilities - Balancing value. Total current liabilities. Deferred income taxes. Senior notes. Recovery Zone facility bonds. Notes payable due to banks. Less unamortized prepaid loan costs. Less current portion. Long-term debt. Noncurrent finance lease liabilities.	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol \$): 2024 2890,551 (2,706,628) (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$\text{ser 21, 2022} \text{rs Ended (\$): 09/28/24} \$353,687,911	 328,539,922	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol \$): 2024 2890,551 (2,706,628) (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$\text{ser 21, 2022} \text{rs Ended (\$): 09/28/24} \$353,687,911	 328,539,922	finance lease liabilities. Property, payroll and other taxes payable. Interest Accrued expenses and current portion of other long-term liabilities - Balancing value. Total current liabilities. Deferred income taxes. Senior notes. Recovery Zone facility bonds. Notes payable due to banks. Less unamortized prepaid loan costs Less current portion. Long-term debt Noncurrent finance lease liabilities. NONCURRENT FINANCE LEASE LIABILITIES	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Net property & equip Total assets Liabilities:	ol. – \$): 2024 183,923 2,890,551 (2,706,628) (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembere Sheet, Year	\$0.66 \$0.66 \$\text{ser 21, 2022} \text{rs Ended (\$): 09/28/24} \$353,687,911	 328,539,922	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary. Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Liabilities: Current liabilities.	ol. – \$): 2024 183,923 2,890,551 (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684	09/30/23 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Net property & equip Total assets Liabilities: Current liabilities Stockholders' equity	ol. – \$): 2024 183,923 2,890,551 (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November ee Sheet, Year	\$0.66 \$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383	09/30/23 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary. Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Liabilities: Current liabilities.	ol. – \$): 2024 183,923 2,890,551 (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembere Sheet, Year	\$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383 462,084,658	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol \$): 2024 183,923 2,890,551 (2,706,628) (0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November the Sheet, Year	\$0.66 \$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383 462,084,658 31,508,803	09/30/23 	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Net property & equip Total assets Liabilities: Current liabilities Stockholders' equity Net current assets NORTHERN TECHNOLOGIES	ol. – \$): 2024 183,923 2,890,551 (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$):	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembers Sheet, Year	\$0.66 \$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383 462,084,658 31,508,803 925,547,755	09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers'	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	ol. – \$): 2024	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP.
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$1, 2022 SE Ended (\$): 09/28/24 \$1, 2022 SE, 741,067 \$1,474,684 \$1,266,383 \$1,508,603 \$1,508,603 \$1,508,603 \$1,508,603 \$1,508,603	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Net property & equip Total assets Liabilities: Current liabilities Stockholders' equity Net current assets NORTHERN TECHNOLOGIES Earnings, 3 mos. to Nov 30(Conso	ol. – \$): 2024 2,890,551 (2,706,628) (2,706,628) (0,16) 16,668,513 17,452,594 s, as of (\$): INTERNATIO ol. – \$): 2024	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP.
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$0.66 78,741,067 474,684 78,266,383 462,084,658 31,508,803 925,547,755 503,677,113 37,545,222	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	DI \$): 2024 2,890,551 (2,706,628) \$(0.16) \$(0.16) 16,668,513 17,452,594 s, as of (\$): INTERNATIO DI \$): 2024 21,338,393	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP.
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 er 21, 2022 rs Ended (\$):	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues . Net Sales . Cost & expenses . Operating income . Interest income . Gains or losses . Net income . Earnings common share . Primary . Fully Diluted . Common Shares: . Full Diluted . Year-end . Consolidated Balance Sheet Item . Assets: . Cash & equivalents . Current assets . Net property & equip . Total assets . Liabilities: . Current liabilities . Stockholders' equity . Net current assets . NORTHERN TECHNOLOGIES . Earnings, 3 mos. to Nov 30(Conso . Total Revenues . Net Sales . Net Sales . Net Sales . Net Sales . Sales . Sales . Consolidated Sales . Sal	DI. – \$): 2024 183,923 2,890,551 (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$): INTERNATIO DI. – \$): 2024 21,338,393	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,255,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$0.66 78,741,067 474,684 78,266,383 462,084,658 31,508,803 925,547,755 503,677,113 37,545,222	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liability insurance	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary. Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Net property & equip. Total assets Liabilities: Current liabilities Stockholders' equity Net current assets. NORTHERN TECHNOLOGIES Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses	DI. – \$): 2024 183,923 2,890,551 (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$): INTERNATIO DI. – \$): 2024 21,338,393 20,231,722	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675 18,805,242
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	405 \$0.66 \$0.66 \$0.66 \$0.67 \$1,2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383 462,084,658 31,508,803 925,547,755 503,677,113 37,545,222 1,470,754,512 1,118,250,135	09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772 1,053,056,285	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liabilities - general liabilities - general liabilities - general liabilitity insurance Other long-term	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179 5,628,963	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Liabilities: Current liabilities Stockholders' equity Net current assets NORTHERN TECHNOLOGIES Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income	DI \$): 2024 2,890,551 (2,706,628) \$(0.16) 16,668,513 17,452,594 s, as of (\$): INTERNATIO DI \$): 2024 21,338,393 20,231,722 1,106,671	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675 20,181,675 20,181,675 20,181,675
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 \$0.66 \$1, 2022 \$1, 2022 \$1, 2022 \$1, 2022 \$2, 241,067 \$1, 208,264 \$1, 208,264 \$1, 208,265 \$1, 508,803	09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772 1,053,056,285 3,656,078	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liability insurance Other long-term liabilities.	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues	2024	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675 18,805,242 1,376,433 46,442
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383 462,084,658 31,508,803 925,547,755 503,677,113 37,545,222 1,470,754,512 1,118,250,135 3,946,422 59,748,005	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772 1,053,056,285 3,656,078 60,950,486	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liabilities . Other long-term	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179 5,628,963 4,804,238	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Liabilities: Current liabilities Stockholders' equity Net current assets NORTHERN TECHNOLOGIES Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income	2024	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675 20,181,675 20,181,675
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of November Sheet, Year	\$0.66 \$0.66 er 21, 2022 rs Ended (\$): 09/28/24 353,687,911 78,741,067 474,684 78,266,383 462,084,658 31,508,803 925,547,755 503,677,113 37,545,222 1,470,754,512 1,118,250,135 3,946,422 59,748,005	09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772 1,053,056,285 3,656,078	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liabilities - general liabilities Other long-term liabilities	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179 5,628,963 4,804,238 48,490,953	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues . Net Sales . Cost & expenses . Operating income . Interest income . Gains or losses . Net income . Earnings common share . Primary . Fully Diluted . Common Shares: . Full Diluted . Year-end . Consolidated Balance Sheet Item . Assets: . Cash & equivalents . Current assets . Net property & equip . Total assets . Liabilities: . Current liabilities . Stockholders' equity . Net current assets . NORTHERN TECHNOLOGIES . Earnings, 3 mos. to Nov 30(Conso . Total Revenues . Net Sales . Cost & expenses . Operating income . Interest expense	2024	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675 18,805,242 1,376,433 46,442 111,138
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembere Sheet, Year	405 \$0.66 \$0.66 \$0.66 \$0.66 \$0.9/28/24 \$1.578,741,067 \$1.508,803	09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772 1,053,056,285 3,656,078 60,950,486 78,531,980	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liability insurance Other long-term liabilities Other long-term liabilities Less current portion Less current portion	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179 5,628,963 4,804,238	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary. Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Net property & equip. Total assets Liabilities: Current liabilities Stockholders' equity Net current assets NORTHERN TECHNOLOGIES Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest income Interest income Interest income Interest expense Net before taxes	2024 183,923 2,706,628 \$(0.16) 16,668,513 17,452,594 s, as of (\$): 2024 21,338,393 20,231,722 1,012,018 1,012,018 217,871 217,871 2017,871 2017,871 2017,871 2017,871 2024 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 2,0231,722 1,012,018 2,0231,722 2,0231,722 1,012,018 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 20,181,675 18,805,242 1,376,433 46,442 111,138 1,311,737
Number of common stockholders - class B	392 5,639,609,434 \$0.66 9,106,047 s of Novembere Sheet, Year	405 \$0.66 \$0.66 \$0.66 \$0.66 \$0.9/28/24 \$1.578,741,067 \$1.508,803	09/30/23 09/30/23 328,539,922 107,714,443 143,753 107,570,690 493,859,775 22,585,958 952,556,345 457,048,257 43,281,401 1,414,696,772 1,053,056,285 3,656,078 60,950,486	finance lease liabilities Property, payroll and other taxes payable Interest Accrued expenses and current portion of other long-term liabilities - Balancing value Total current liabilities Deferred income taxes Senior notes Recovery Zone facility bonds Notes payable due to banks Less unamortized prepaid loan costs Less current portion Long-term debt Noncurrent finance lease liabilities NONCURRENT FINANCE LEASE LIABILITIES Noncurrent operating lease liabilities Advance payments on purchases contracts Nonqualified investment plan liability Self-insurance liabilities - workers' compensation insurance Self-insurance liabilities - general liabilities - general liabilities Other long-term liabilities	22,592,669 4,984,248 16,477,444 320,621,944 63,767,000 2,385,179 24,276,818 	330,533,149 67,187,000 350,000,000 54,440,000 151,069,954 (5,351,705) 17,526,289 532,631,960 3,059,938 34,016,670 2,992,494 21,768,079 13,297,179 5,628,963 4,804,238 48,490,953	20250.17 LEXARIA BIOSCIENCE CORP Earnings, 3 mos. to Nov 30(Conso Total Revenues. Net Sales. Cost & expenses Operating income Interest income Gains or losses Net income Earnings common share Primary. Fully Diluted Common Shares: Full Diluted Year-end Consolidated Balance Sheet Item Assets: Cash & equivalents Current assets Liabilities: Current liabilities. Stockholders' equity Net current assets NorTHERN TECHNOLOGIES Earnings, 3 mos. to Nov 30(Conso Total Revenues Net Sales Cost & expenses Operating income Interest expense Net Defore taxes Income taxes.	2024 183,923 2,706,628 \$(0.16) 16,668,513 17,452,594 s, as of (\$): 2024 21,338,393 20,231,722 1,012,018 1,012,018 217,871 217,871 2017,871 2017,871 2017,871 2017,871 2024 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 1,012,018 2,0231,722 2,0231,722 1,012,018 2,0231,722 2,0231,722 1,012,018 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722 2,0231,722	2023 151,278 151,278 1,290,420 (1,185,038) 7,319 (53,215) (1,185,038) \$(0.13) \$(0.13) \$(0.13) 9,051,531 10,311,641 2024 8,078,254 8,825,741 270,621 9,793,774 297,798 9,774,334 8,527,943 NAL CORP. 2023 20,181,675 18,805,242 1,376,433 46,442 111,138 1,311,737 226,796

Primary		\$0.09	TILRAY BRANDS INC	φορο)		Net current assets	155,299
Fully Diluted	\$0.06	\$0.09	Earnings, 6 mos. to Nov 30(Conso		2022		
Common Shares:	0.551.000	0.506.501	T . 15	2024			
Full Diluted		9,706,581	Total Revenues		370,720		
Year-end	9,470,507	9,427,598	Net Sales		370,720		
Consolidated Balance Sheet Items, a	s of (\$):		Cost & expenses		402,699		
Assets:	(+).	2024	Operating income	. (78,788)	(76,121)		
Cash & equivalents			Interest expense		18,460		
Inventories			Other income (expense), net	. (185)	(9,174)		
			Gains or losses	. 1,492	350		
Current assets			Foreign currency		5,243		
Net property & equip			Net before taxes				
Total assets		94,037,655	Income taxes		3,884		
Liabilities:			Net income	, , , , , , , , , , , , , , , , , , , ,			
Current liabilities			Earnings common share	. (11),)21)	(102,040)		
Stockholders' equity			2	\$(0.14)	\$(0.17)		
Net current assets		22,183,428	Primary				
			Fully Diluted	\$(0.14)	\$(0.17)		
OCEAN BIOMEDICAL INC			Common Shares:	027 400	510.050		
Earnings, 9 mos. to Sep 30(Consol	- \$):		Full Diluted		710,878		
zarmings, s most to pep to (comson	2024	2023	Year-end	925,575	732,908		
Cost & expenses							
			WALGREENS BOOTS ALLIANO	CE INC			
Operating income			Earnings, 3 mos. to Nov 30(Consol	l. – \$000):			
Other income (expense), net		(24,504,000)	•	2024	2023		
Gains or losses			Total Revenues				
Net income	(9,763,000)	(97,610,000)	Net Sales				
Earnings common share			Cost & expenses				
Primary			Operating income				
Fully Diluted	\$(0.36)	\$(3.76)	Interest expense		99,000		
Common Shares:					,		
Full Diluted	27,446,868	25,980,292	Other income (expense), net				
Year-end			Equity earnings		(6,000)		
	, -,	, .,	Net before taxes	. , ,			
RADIUS RECYCLING INC			Income taxes	,	(74,000)		
	\$000).		Net income	. (605,000)	(278,000)		
Earnings, 3 mos. to Nov 30(Consol		2022	Earnings common share				
m . 1 p	2024		Primary	\$(0.31)	\$(0.08)		
Total Revenues	656,537	672,897	Fully Diluted	\$(0.31)	\$(0.08)		
Cost & expenses	681,449	695,884	Common Shares:				
Operating income	(24,912)		Full Diluted	863,800	863,000		
Interest expense		4,810	Year-end		862,167		
Other income (expense), net	636	(170)			, , , , ,		
Net before taxes	(33,138)	(27,967)	Consolidated Balance Sheet Items	, as of (5000):	2024		
Income taxes	3,791	(10,170)	Assets:		2024		
Income contin. oper			Cash & equivalents		859,000		
Income discont. oper			Inventories				
Net income	(36,929)		Current assets		17,478,000		
Earnings common share	(= =,, =,)	(=-,)	Net property & equip		9,382,000		
Primary	. \$(1.30)	\$(0.64)	Total assets		78,536,000		
			Liabilities:				
Fully Diluted	. \$(1.30)	\$(0.04)	Current liabilities		27.453.000		
Common Shares:	20.552	20.210	Long-term debt				
Full Diluted		28,219	Stockholders' equity				
Year-end	28,155	27,863	Net current assets				
Consolidated Balance Sheet Items, a	s of (\$000):		Net current assets		(9,975,000)		
Assets:	(, , .	2024	WD-40 CO				
Cash & equivalents		15,223		\$000			
Inventories		306,360	Earnings, 3 mos. to Nov 30(Consol		2022		
Current assets		588,264	T : 1 D	2024			
			Total Revenues		140,416		
Net property & equip		658,487	Net Sales		140,416		
Total assets		1,510,794	Cost & expenses		115,981		
Liabilities:		201 (54	Operating income		24,184		
Current liabilities		291,654	Interest income		74		
Long-term debt		439,872	Interest expense		1,146		
Stockholders' equity		580,430	Other income (expense), net		(40)		
Net current assets		296,610	Net before taxes		23,072		
			Income taxes		5,590		
RICHARDSON ELECTRONICS LT	ΓD		Net income		17,482		
Earnings, 6 mos. to (Consol \$000)	:		Balance for common				
5, (4000)	11/30/24	12/02/23	Earnings common share	. 13,001			
Total Revenues	103,216	96,711		\$1.39	\$1.28		
Net Sales			Primary				
	103,567	97,255	Fully Diluted	\$1.39	\$1.28		
Cost & expenses			Common Shares:	10.555	12.50:		
Operating income	(351)		Full Diluted		13,584		
Other income (expense), net	104	(50)	Year-end	13,550	13,558		
Foreign currency			Consolidated Balance Sheet Items	, as of (\$000):			
Net before taxes	(407)		Assets:		2024		
	(246)		Cash & equivalents		54,914		
Income taxes					74,887		
Income taxes	(161)	(570)	Inventories		/ +,00 /		
Income taxes	(161)	(570)	Inventories				
Income taxes Net income			Current assets		262,801		
Income taxes	. \$(0.01)	\$(0.04)	Current assets		262,801 59,384		
Income taxes. Net income Earnings common share Primary Fully Diluted	. \$(0.01)	\$(0.04)	Current assets		262,801		
Income taxes	\$(0.01) \$(0.01)	\$(0.04) \$(0.04)	Current assets		262,801 59,384 447,324		
Income taxes. Net income Earnings common share Primary Fully Diluted Common Shares: Full Diluted.	\$(0.01) \$(0.01) . 14,307	\$(0.04) \$(0.04) 14,250	Current assets Net property & equip. Total assets Liabilities: Current liabilities		262,801 59,384 447,324 107,502		
Income taxes	\$(0.01) \$(0.01) . 14,307	\$(0.04) \$(0.04)	Current assets		262,801 59,384 447,324		

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2025 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.